Role of micro-RNAs 21, 124 and other novel biomarkers in distinguishing between group 1 WHO pulmonary hypertension and group 2, 3 WHO pulmonary hypertension
Tóm tắt
Pulmonary hypertension “PH” is considered a serious cardiovascular disease. World Health Organization divided PH into groups depending on many factors like pathological, hemodynamic, and clinical pictures. Lately, various micro-RNAs “miRNAs” and other novel biomarkers like endoglin and asymmetric dimethylarginine “ADMA” might have a role in diagnosis of PH and may differentiate between pulmonary arterial hypertension “PAH” and non-PAH. The purpose of the study is to show the role of miR-21, miR-124, endoglin and ADMA in the diagnosis of PH and distinguishing between WHO group 1 PH and WHO group 2 and 3 PH and to identify patients who might benefit from non-invasive and inexpensive tools to diagnose PAH. miR-21 was upregulated in group 1 PH, and there was significant difference between group 1 PH as compared with group 2 PH, group 3 PH and control; miR-124 was down-regulated in group 1 PH with highly significant difference between group 1 and group 2 PH and control but no significant difference with group 3 PH, endoglin was elevated in group 1 PH with a significant difference as compared to group 2 PH, group 3 PH and control. ADMA was elevated in group 1 PH as compared to control; however, there was no significant difference between it and group 2, 3 PH. miR-21, miR-124, endoglin and ADMA are good biomarkers to diagnose PH; however, only miR-21 and endoglin could distinguish group 1 PH from group 2 and 3 PH.
Tài liệu tham khảo
Simonneau G, Montani D, Celermajer DS et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53:1801913
Galie N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed) 69:177
Galie N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119
Price LC, Weatherald J (2023) The new 2022 pulmonary hypertension guidelines: some small steps and some giant leaps forward for evidence-based care. Eur Respir J 61:2202150
Oudiz RJ (2007) Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 28:233–241
Thabut G, Dauriat G, Stern JB et al (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127:1531–1536
Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR et al (2019) Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 53:1801887
Min PK, Chan SY (2015) The biology of circulating microRNAs in cardiovascular disease. Eur J Clin Investig 45:860–874
Chun HJ, Bonnet S, Chan SY (2016) Translating microRNA biology in pulmonary hypertension: it will take more than “miR” words. Am J Respir Crit Care Med 195:167–178
Van Rooij E, Olson EN (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Investig 117:2369–2376
Zhang S, Yang T, Xu X, Wang M, Zhong L, Yang Y, Zhai Z, Xiao F, Wang C (2015) Oxidative stress and nitric oxide signaling related biomarkers in patients with pulmonary hypertension: a case control study. BMC Pulm Med 15:50
Shafran I, Probst V, Campean J et al (2020) The role of asymmetric dimethylarginine (ADMA) in the follow-up of patients with precapillary pulmonary hypertension (PH). Eur Heart J 41(Supplement_2):ehaa946.2303
Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W et al (2013) Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ 3:369–380
Yuan Z, Luo G, Li X, Chen J, Wu J, Peng Y (2016) PPARc inhibits HMGB1 expression through upregulation of miR-142-3p in vitro and in vivo. Cell Signal 28(3):158–164
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101
Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M et al (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137:376–387
Montani D, Gunther S, Dorfmuller P, Perros F, Girerd B, Garcia G, Jais X, Savale L, Artaud-Macari E, Price LC et al (2013) Pulmonary arterial hypertension. Orphanet J Rare Dis 8:97
Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F (2011) microRNAs as peripheral blood biomarkers of cardiovascular disease. Vasc Pharmacol 55:111–118
Xiaoyi Hu, Wang Q, Zhao H et al (2022) Role of miR-21-5p/FilGAP axis in estradiol alleviating the progression of monocrotaline-induced pulmonary hypertension. Anim Model Exp Med 5(3):217–226
Parikh VN, Jin RC, Rabello S et al (2012) MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension. Circulation 125:1520–1532
Kang K, Peng X, Zhang X, Wang Y, Zhang L, Gao L, Weng T, Zhang H, Ramchandran R, Raj JU et al (2013) MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem 288:25414–25427
Caruso P, Dunmore BJ, Schlosser K, Schoors S, Dos Santos C, Perez-Iratxeta C, Lavoie JR, Zhang H, Long L, Flockton AR et al (2017) Identification of microRNA-124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1 (polypyrimidine tract binding protein) and pyruvate kinase M2. Circulation 136:2451–2467
Zhang H, Laux A, Stenmark KR et al (2021) Mechanisms contributing to the dysregulation of miRNA-124 in pulmonary hypertension. Int J Mol Sci 22(8):3852
Zhang H, Wang D, Li M (2017) Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA-124/PTBP1 (polypyrimidine tract binding protein 1)/pyruvate kinase muscle axis. Circulation 136:2468–2485
Ruiz-Llorente L, Gallardo-Vara E, Rossi E, Smadja DM, Botella LM, Bernabeu C (2017) Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets 21:933–947
Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CPH, Bernabeu C (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor receptor complex. J Cell Physiol 204:574–584
Toporsian M, Jerkic M, Zhou YQ, Kabir MG, Yu LX, McIntyre BAS, Davis A, Wang YJ, Stewart DJ, Belik J (2010) Spontaneous adultonset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol 30:509–517
Gregory AL, Xu G, Sotov V, Letarte M (2014) Review: the enigmatic role of endoglin in the placenta. Placenta 35:93–99
Al-Dujaili MN, Hussein K, Al-Khafaji A et al (2018) Endoglin level in pulmonary arterial hypertension patients and its association with some criteria. J Pharm Sci Res 10:644–651
Coral-Alvarado PX, Garces MF, Caminos JE, Iglesias-Gamarra A, Restrepo JF, Quintana G (2010) Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol 2010:969383
Böger RH, Maas R, Schulze F, Schwedhelm E (2009) Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality—an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 60:481–487
Böger RH, Endres HG, Schwedhelm E, Darius H, Atzler D, Lüneburg N et al (2011) Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J Intern Med 269:349–361
Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62:2425–2430
Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE (2001) Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37:489–492
Scott JA, North ML, Rafii M, Huang H, Pencharz P, Subbarao P et al (2011) Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med 184:779–785
Di Gangi IM, Pirillo P, Carraro S, Gucciardi A, Naturale M, Baraldi E et al (2012) Online trapping and enrichment ultra performance liquid chromatography-tandem mass spectrometry method for sensitive measurement of “arginine-asymmetric dimethylarginine cycle” biomarkers in human exhaled breath condensate. Anal Chim Acta 754:67–74
Liu J, Fu Q, Jiang L et al (2019) Clinical value of asymmetrical dimethylarginine detection in patients with connective tissue disease-associated pulmonary arterial hypertension. Cardiol Res Pract 2019:1–8